Cargando…
Intranasal dexamethasone: a new clinical trial for the control of inflammation and neuroinflammation in COVID-19 patients
BACKGROUND: By end December of 2021, COVID-19 has infected around 276 million individuals and caused over 5 million deaths worldwide. Infection results in dysregulated systemic inflammation, multi-organ dysfunction, and critical illness. Cells of the central nervous system are also affected, trigger...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8845269/ https://www.ncbi.nlm.nih.gov/pubmed/35164840 http://dx.doi.org/10.1186/s13063-022-06075-5 |